There is always some stupid irrelevant publication that comes out just when AAPL is trying to recover. Seems so intentional. Everyone knows its all about the iphone and tablet sales don't matter that much now. ggggrrrrr
...Demand for tablet computers is continuing to plunge, according to data released Wednesday from Framingham-based research firm International Data Corp.
The worldwide tablet market declined 7 percent year over year in the second quarter of 2015 with shipments totaling 44.7 million units, IDC reported.
Marked by little hardware innovation and limited vendor portfolio updates, the market also declined 3.9 percent compared to the first quarter of 2015, the report noted.
I'm baffled! No viable reason for this to be down unless its options pinning again.
Bank of America appears to be the only bear: Gilead Sciences Inc. (NASDAQ: GILD) shares were trading up 35 at $116.75 or so in early Wednesday trading after beating earnings Tuesday evening. Gilead was reiterated as Outperform and the price target was raised to $130 from $120 at RBC Capital Markets. BofA Merrill Lynch reiterated an Underperform rating with a $107 price objective.
Even more frustrating some damned restaurant company that pushes chicken wings is up 15% on so-so earnings.
Take a look at ANTH. I could kick myself for freaking out and bailing on it when they did yet another secondary offering after just concluding the first. It dipped then took off again. Now I keep waiting for a dip to get back into the stock but it is up $2.00 since I bailed a couple of weeks ago. The one that got away. It Is trading around $11.00. Chart it and you'll see exactly what I'm talking about. I think I'll wait until they report as it may fall hard if they disappoint after this huge run. They apparently have something someone wants in their patents.
They didn't beat, Huge miss on the revenues. EPS was a beat but that's not what matters. They missed revs and then they lowered full year guidance. Most hated company on Wall Street this morning.
Exactly. BIIB big miss on less than expected MS drug sales and lowering guidance full year. All the ETF's and funds will take a hit by association. Stinks.